Institutions / Boxer Capital Management, LLC / Activity

Activity — Boxer Capital Management, LLC

38 moves.

BiggestNew positionsBiggest addsExits
InsidersInstitutions
DateActionCompanyValueShares ΔPosition afterImpact
Q4 2025
as of
NewTerns Pharmaceuticals, Inc.
Common stock
$15.15M+375K
375,000
3.32% of portfolio
medium
Q4 2025
as of
NewPraxis Precision Medicines, Inc.
Common stock
$13.69M+46K
46,457
3.00% of portfolio
medium
Q3 2025
as of
NewPTC Therapeutics Inc
Common stock
$12.27M+200K
200,000
2.69% of portfolio
medium
Q4 2025
as of
NewPalisade Bio, Inc.
Common stock
$11.28M+4.8M
4,799,875
2.47% of portfolio
medium
Q3 2025
as of
NewCytokinetics Inc
Common stock
$10.99M+200K
200,000
2.41% of portfolio
medium
Q3 2025
as of
New00370M103
Common stock
$10.19M+120K
120,000
2.23% of portfolio
medium
Q4 2025
as of
NewSRZN
Surrozen, Inc./DE
Common Stock
$9.40M+416K
416,150
2.06% of portfolio
medium
Q4 2025
as of
NewCapricor Therapeutics, Inc.
Common stock
$9.38M+325K
325,000
2.05% of portfolio
medium
Q2 2025
as of
New46565G104
Common stock
$8.23M+825K
825,000
1.80% of portfolio
medium
Q4 2025
as of
NewCogent Biosciences, Inc.
Common stock
$7.99M+225K
225,000
1.75% of portfolio
medium
Q2 2025
as of
NewM96088105
Common stock
$7.88M+575K
575,000
1.72% of portfolio
medium
Q2 2025
as of
NewCrescent Biopharma, Inc.
Common stock
$7.32M+454K
453,686
1.60% of portfolio
medium
Q4 2025
as of
NewCybin Inc.
Common stock
$5.85M+715K
715,000
1.28% of portfolio
medium
Q4 2025
as of
NewContineum Therapeutics, Inc.
Common stock
$5.65M+494K
494,000
1.24% of portfolio
medium
Q3 2025
as of
NewInovio Pharmaceuticals, Inc.
Common stock
$5.38M+2.3M
2,300,000
1.18% of portfolio
medium
Q4 2025
as of
NewGPCR
Structure Therapeutics Inc.
ADR
$5.22M+75K
75,000
1.14% of portfolio
medium
Q3 2025
as of
NewCELC
Celcuity Inc.
Common Stock
$4.45M+90K
90,000
0.97% of portfolio
low
Q4 2025
as of
NewUPB
Upstream Bio, Inc.
Common Stock
$4.07M+150K
150,000
0.89% of portfolio
low
Q4 2025
as of
NewVir Biotechnology, Inc.
Common stock
$3.77M+625K
625,000
0.82% of portfolio
low
Q4 2025
as of
NewInvivyd, Inc.
Common stock
$3.71M+1.5M
1,500,000
0.81% of portfolio
low
Q3 2025
as of
NewSLDB
Solid Biosciences Inc.
Common Stock
$3.70M+600K
600,000
0.81% of portfolio
low
Q3 2025
as of
NewDenali Therapeutics Inc.
Common stock
$3.63M+250K
250,000
0.79% of portfolio
low
Q2 2025
as of
NewProtagonist Therapeutics Inc
Common stock
$3.32M+60K
60,000
0.73% of portfolio
low
Q2 2025
as of
NewNektar Therapeutics
Common stock
$3.23M+125K
125,000
0.71% of portfolio
low
Q3 2025
as of
NewPrecigen, Inc.
Common stock
$2.80M+850K
850,000
0.61% of portfolio
low
Q2 2025
as of
New171757206
Common stock
$2.68M+55K
55,000
0.59% of portfolio
low
Q3 2025
as of
NewApogee Therapeutics, Inc.
Common stock
$1.99M+50K
50,000
0.43% of portfolio
low
Q3 2025
as of
New60255C885
Common stock
$1.93M+164K
163,500
0.42% of portfolio
low
Q4 2025
as of
NewKaryopharm Therapeutics Inc.
Common stock
$1.86M+253K
252,536
0.41% of portfolio
low
Q3 2025
as of
NewMLTX
MoonLake Immunotherapeutics
Common Stock
$1.79M+250K
250,000
0.39% of portfolio
low
Q3 2025
as of
NewAvalo Therapeutics, Inc.
Common stock
$1.59M+125K
125,000
0.35% of portfolio
low
Q3 2025
as of
NewMilestone Pharmaceuticals Inc.
Common stock
$1.33M+667K
666,666
0.29% of portfolio
low
Q4 2025
as of
NewCLNN
Clene Inc.
Common Stock
$1.17M+200K
199,737
0.26% of portfolio
low
Q3 2025
as of
NewPepGen Inc.
Common stock
$1.16M+250K
250,000
0.25% of portfolio
low
Q3 2025
as of
NewLBRX
Lb Pharmaceuticals Inc
Common Stock
$1.11M+70K
70,000
0.24% of portfolio
low
Q2 2025
as of
NewKalVista Pharmaceuticals Inc
Common stock
$1.06M+93K
93,400
0.23% of portfolio
low
Q2 2025
as of
NewSarepta Therapeutics, Inc.
Common stock
$427.5K+25K
25,000
0.09% of portfolio
low
Q4 2025
as of
NewZura Bio Limited
Common stock
$262.0K+50K
50,000
0.06% of portfolio
low
← PrevPage 1 of 1Next →